472 related articles for article (PubMed ID: 27940601)
1. Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity.
Smith LM; Strittmatter SM
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 27940601
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains.
Takahashi RH; Yokotsuka M; Tobiume M; Sato Y; Hasegawa H; Nagao T; Gouras GK
Brain Pathol; 2021 Sep; 31(5):e12941. PubMed ID: 33624334
[TBL] [Abstract][Full Text] [Related]
3. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
[TBL] [Abstract][Full Text] [Related]
4. Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.
Aimi T; Suzuki K; Hoshino T; Mizushima T
J Neurochem; 2015 Aug; 134(4):611-7. PubMed ID: 25963375
[TBL] [Abstract][Full Text] [Related]
5. A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein.
Rösener NS; Gremer L; Reinartz E; König A; Brener O; Heise H; Hoyer W; Neudecker P; Willbold D
J Biol Chem; 2018 Oct; 293(41):15748-15764. PubMed ID: 30131337
[TBL] [Abstract][Full Text] [Related]
6. Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity.
Pagano K; Galante D; D'Arrigo C; Corsaro A; Nizzari M; Florio T; Molinari H; Tomaselli S; Ragona L
Mol Neurobiol; 2019 Mar; 56(3):1957-1971. PubMed ID: 29981054
[TBL] [Abstract][Full Text] [Related]
7. Binding between Prion Protein and Aβ Oligomers Contributes to the Pathogenesis of Alzheimer's Disease.
Kong C; Xie H; Gao Z; Shao M; Li H; Shi R; Cai L; Gao S; Sun T; Li C
Virol Sin; 2019 Oct; 34(5):475-488. PubMed ID: 31093882
[TBL] [Abstract][Full Text] [Related]
8. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
9. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"].
Tamaoka A
Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113
[TBL] [Abstract][Full Text] [Related]
10. Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5.
Brody AH; Strittmatter SM
Adv Pharmacol; 2018; 82():293-323. PubMed ID: 29413525
[TBL] [Abstract][Full Text] [Related]
11. Prion protein stabilizes amyloid-β (Aβ) oligomers and enhances Aβ neurotoxicity in a
Younan ND; Chen KF; Rose RS; Crowther DC; Viles JH
J Biol Chem; 2018 Aug; 293(34):13090-13099. PubMed ID: 29887525
[TBL] [Abstract][Full Text] [Related]
12. Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease.
Nygaard HB; Strittmatter SM
Arch Neurol; 2009 Nov; 66(11):1325-8. PubMed ID: 19901162
[TBL] [Abstract][Full Text] [Related]
13. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
Brody DL; Jiang H; Wildburger N; Esparza TJ
Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
[TBL] [Abstract][Full Text] [Related]
14. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
Laurén J; Gimbel DA; Nygaard HB; Gilbert JW; Strittmatter SM
Nature; 2009 Feb; 457(7233):1128-32. PubMed ID: 19242475
[TBL] [Abstract][Full Text] [Related]
15. Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy.
König AS; Rösener NS; Gremer L; Tusche M; Flender D; Reinartz E; Hoyer W; Neudecker P; Willbold D; Heise H
J Biol Chem; 2021; 296():100499. PubMed ID: 33667547
[TBL] [Abstract][Full Text] [Related]
16. Preferential Recruitment of Conformationally Distinct Amyloid-β Oligomers by the Intrinsically Disordered Region of the Human Prion Protein.
Madhu P; Mukhopadhyay S
ACS Chem Neurosci; 2020 Jan; 11(1):86-98. PubMed ID: 31808343
[TBL] [Abstract][Full Text] [Related]
17. The pathogenesis of soluble PrP fragments containing Aβ binding sites.
Li B
Virus Res; 2016 Jan; 211():194-8. PubMed ID: 26528810
[TBL] [Abstract][Full Text] [Related]
18. Brain amyloid-β oligomers in ageing and Alzheimer's disease.
Lesné SE; Sherman MA; Grant M; Kuskowski M; Schneider JA; Bennett DA; Ashe KH
Brain; 2013 May; 136(Pt 5):1383-98. PubMed ID: 23576130
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.
Limegrover CS; LeVine H; Izzo NJ; Yurko R; Mozzoni K; Rehak C; Sadlek K; Safferstein H; Catalano SM
J Neurochem; 2021 May; 157(4):1316-1330. PubMed ID: 33025581
[TBL] [Abstract][Full Text] [Related]
20. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance.
Smith LM; Kostylev MA; Lee S; Strittmatter SM
J Biol Chem; 2019 Apr; 294(15):6042-6053. PubMed ID: 30787106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
